Leap Therapeutics Inc
Company Profile
Business description
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
Contact
47 Thorndike Street
Suite B1-1
CambridgeMA02141
USAT: +1 617 714-0360
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
52
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,826.70 | 48.80 | 0.56% |
CAC 40 | 7,902.25 | 23.79 | 0.30% |
DAX 40 | 24,456.81 | 92.75 | -0.38% |
Dow JONES (US) | 44,650.64 | 192.34 | 0.43% |
FTSE 100 | 8,975.66 | 108.64 | 1.23% |
HKSE | 24,028.37 | 136.05 | 0.57% |
NASDAQ | 20,630.66 | 19.33 | 0.09% |
Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
NZX 50 Index | 12,800.22 | 40.02 | 0.31% |
S&P 500 | 6,280.46 | 17.20 | 0.27% |
S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
SSE Composite Index | 3,509.68 | 16.63 | 0.48% |